What is the virus that is viral fever of humans and primates and that Triazavirin could have a potential application?
Triazavirin Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has an azoloazine base structure, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis, and is also being investigated for potential application against Lassa fever and Ebola virus disease.
Sphaerolipoviridae Sphaerolipoviridae is a family of double-stranded DNA viruses that infect thermophilic bacteria and halophilic archea, formally approved by the International Committee on Taxonomy of Viruses in 2015. Viruses of this family have tailless icosahedral virions with an internal lipid membrane located between the protein capsid and the double-stranded DNA genome. Overall virion organization of sphaerolipoviruses is similar to that of viruses belonging to the families "Tectiviridae", "Corticoviridae" and "Turriviridae".